Prostate Cancer - Pipeline Review, H1 2018

  • ID: 4586014
  • Report
  • 2069 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BeiGene Ltd
  • Eli Lilly and Co
  • Immuneed AB
  • NewLink Genetics Corp
  • Selexel Sarl
  • MORE
Prostate Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 118, 103, 7, 243, 34 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 20, 58 and 21 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BeiGene Ltd
  • Eli Lilly and Co
  • Immuneed AB
  • NewLink Genetics Corp
  • Selexel Sarl
  • MORE
Introduction

Prostate Cancer - Overview

Prostate Cancer - Therapeutics Development

Prostate Cancer - Therapeutics Assessment

Prostate Cancer - Companies Involved in Therapeutics Development

Prostate Cancer - Drug Profiles

Prostate Cancer - Discontinued Products

Prostate Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Prostate Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Prostate Cancer - Pipeline by 3-V Biosciences Inc, H1 2018

Prostate Cancer - Pipeline by 4SC AG, H1 2018

Prostate Cancer - Pipeline by AB Science SA, H1 2018

Prostate Cancer - Pipeline by AbbVie Inc, H1 2018

Prostate Cancer - Pipeline by Abpro, H1 2018

Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Prostate Cancer - Pipeline by ADC Therapeutics SA, H1 2018

Prostate Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2018

Prostate Cancer - Pipeline by Advantagene Inc, H1 2018

Prostate Cancer - Pipeline by Advaxis Inc, H1 2018

Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018

Prostate Cancer - Pipeline by Akshaya Bio Inc, H1 2018

Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018

Prostate Cancer - Pipeline by Alissa Pharma, H1 2018

Prostate Cancer - Pipeline by ALRISE Biosystems GmbH, H1 2018

Prostate Cancer - Pipeline by Altor BioScience Corp, H1 2018

Prostate Cancer - Pipeline by Ambrx Inc, H1 2018

Prostate Cancer - Pipeline by Amgen Inc, H1 2018

Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H1 2018

Prostate Cancer - Pipeline by AndroScience Corp, H1 2018

Prostate Cancer - Pipeline by AnGes Inc, H1 2018

Prostate Cancer - Pipeline by AntiCancer Inc, H1 2018

Prostate Cancer - Pipeline by Antigen Express Inc, H1 2018

Prostate Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018

Prostate Cancer - Pipeline by Apcure SAS, H1 2018

Prostate Cancer - Pipeline by Aphios Corp, H1 2018

Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2018

Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H1 2018

Prostate Cancer - Pipeline by Aptose Biosciences Inc, H1 2018

Prostate Cancer - Pipeline by ARMO Biosciences Inc, H1 2018

Prostate Cancer - Pipeline by Armour Therapeutics Inc, H1 2018

Prostate Cancer - Pipeline by ArQule Inc, H1 2018

Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018

Prostate Cancer - Pipeline by Arvinas Inc, H1 2018

Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018

Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2018

Prostate Cancer - Pipeline by Athenex Inc, H1 2018

Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Prostate Cancer - Pipeline by Autolus Ltd, H1 2018

Prostate Cancer - Pipeline by Avivia BV, H1 2018

Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Prostate Cancer - Pipeline by Bayer AG, H1 2018

Prostate Cancer - Pipeline by BeiGene Ltd, H1 2018

Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2018

Prostate Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Prostate Cancer - Pipeline by BioAtla LLC, H1 2018

Prostate Cancer - Pipeline by BioNTech AG, H1 2018

Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018

Prostate Cancer - Pipeline by Blirt SA, H1 2018

Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Prostate Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Prostate Cancer - Pipeline by Bukwang Pharm Co Ltd, H1 2018

Prostate Cancer - Pipeline by Camurus AB, H1 2018

Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Prostate Cancer - Pipeline by CanBas Co Ltd, H1 2018

List of Figures

Number of Products under Development for Prostate Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • Abpro
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Advanced Cancer Therapeutics LLC
  • Advantagene Inc
  • Advaxis Inc
  • Aeglea BioTherapeutics Inc
  • Aeolus Pharmaceuticals Inc
  • Akshaya Bio Inc
  • Alethia Biotherapeutics Inc
  • Alissa Pharma
  • ALRISE Biosystems GmbH
  • Altor BioScience Corp
  • Ambrx Inc
  • Amgen Inc
  • Anavex Life Sciences Corp
  • AndroScience Corp
  • AnGes Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • Antikor Biopharma Ltd
  • Apcure SAS
  • Aphios Corp
  • APIM Therapeutics AS
  • Aptevo Therapeutics Inc
  • Aptose Biosciences Inc
  • ARMO Biosciences Inc
  • Armour Therapeutics Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • Arrowhead Pharmaceuticals Inc
  • Arvinas Inc
  • Asieris Pharmaceuticals Co Ltd
  • AstraZeneca Plc
  • Athenex Inc
  • Aurigene Discovery Technologies Ltd
  • Autolus Ltd
  • Avivia BV
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bexion Pharmaceuticals LLC
  • BeyondSpring Pharmaceuticals Inc
  • Bio-Cancer Treatment International Ltd
  • BioAtla LLC
  • BioNTech AG
  • Biscayne Pharmaceuticals Inc
  • Blirt SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Bukwang Pharm Co Ltd
  • Camurus AB
  • Can-Fite BioPharma Ltd
  • CanBas Co Ltd
  • Cantex Pharmaceuticals Inc
  • Celgene Corp
  • CellCentric Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellestia Biotech AG
  • Cellmid Ltd
  • Cells for Cells SA
  • Cellular Biomedicine Group Inc
  • Celprogen Inc
  • Clovis Oncology Inc
  • CohBar Inc
  • Colby Pharmaceutical Co
  • Corcept Therapeutics Inc
  • Corvus Pharmaceuticals Inc
  • Crescendo Biologics Ltd
  • Cristal Therapeutics BV
  • Curadis GmbH
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • CytoVac AS
  • CZ BioMed Corp
  • Daewon Pharm Co Ltd
  • Daewoong Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Deciphera Pharmaceuticals LLC
  • DEKK-TEC Inc
  • DexTech Medical AB
  • Diffusion Pharmaceuticals Inc
  • DNJ Pharma Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enceladus Pharmaceuticals BV
  • EndoCeutics Inc
  • Endocyte Inc
  • EntreChem SL
  • EOS Biosciences Inc
  • Errant Gene Therapeutics LLC
  • Esperance Pharmaceuticals Inc
  • ESSA Pharma Inc
  • Eureka Therapeutics Inc
  • Evgen Pharma Plc
  • F. Hoffmann-La Roche Ltd
  • Felicitex Therapeutics Inc
  • Ferring International Center SA
  • Fountain Biopharma Inc
  • Fujifilm Holdings Corporation
  • G1 Therapeutics Inc
  • Galectin Therapeutics Inc
  • GemVax & KAEL Co Ltd
  • Genelux Corp
  • Genentech Inc
  • GeneSegues Inc
  • GenKyoTex SA
  • Genmab A/S
  • Gilead Sciences Inc
  • Glactone Pharma AB
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • GP Pharm SA
  • GTx Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Harpoon Therapeutics Inc
  • Health Ever Bio-Tech Co Ltd
  • Heidelberg Pharma AG
  • HitGen LTD
  • Hookipa Biotech AG
  • Humanigen Inc
  • Hutchison MediPharma Ltd
  • Hybrigenics SA
  • IC-MedTech Inc
  • ID Pharma Co Ltd
  • Ideaya Biosciences Inc
  • IGF Oncology LLC
  • Ildong Pharmaceutical Co Ltd
  • Immune Pharmaceuticals Inc
  • Immuneed AB
  • Immunocore Ltd
  • ImmunoFrontier Inc
  • Immunomedics Inc
  • IMPACT Therapeutics Inc
  • Incanthera Ltd
  • Inflection Biosciences Ltd
  • InKemia IUCT Group SA
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Io Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Karyopharm Therapeutics Inc
  • Kiromic Inc
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kringle Pharma Inc
  • Kura Oncology Inc
  • LATITUDE Pharmaceuticals Inc
  • Lidds AB
  • Luye Pharma Group Ltd
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc
  • MallInckrodt Plc
  • Mateon Therapeutics Inc
  • MaxiVAX SA
  • Med Discovery SA
  • MediaPharma SRL
  • MediGene AG
  • MedImmune LLC
  • Mediolanum farmaceutici SpA
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Minerva Biotechnologies Corp
  • Mirati Therapeutics Inc
  • Mithra Pharmaceuticals SA
  • Mitsubishi Tanabe Pharma Corp
  • Molecular Templates Inc
  • Monopar Therapeutics Inc
  • Morphotek Inc
  • MTG Biotherapeutics Inc
  • NantKwest Inc
  • NewLink Genetics Corp
  • NormOxys Inc
  • Novartis AG
  • Noxopharm Ltd
  • Nymox Pharmaceutical Corp
  • Omeros Corp
  • Omnitura Therapeutics Inc
  • OncBioMune Pharmaceuticals Inc
  • Oncodrone BV
  • OncoNOx ApS
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Oncternal Therapeutics Inc
  • Oneness Biotech Co Ltd
  • Ono Pharmaceutical Co Ltd
  • ORCA Therapeutics BV
  • Oric Pharmaceuticals Inc
  • Orion Corporation
  • Patrys Ltd
  • PDS Biotechnology Corp
  • Peptron Inc
  • PepVax Inc
  • Pfizer Inc
  • Pharmedartis GmbH
  • Pharmicell Co Ltd
  • Philogen SpA
  • Phosplatin Therapeutics LLC
  • Polaris Pharmaceuticals Inc
  • Polyplus-Transfection SA
  • Poseida Therapeutics Inc
  • Progenics Pharmaceuticals Inc
  • Provectus Biopharmaceuticals Inc
  • Provenance Biopharmaceuticals Corp
  • PTC Therapeutics Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Regulaxis SAS
  • RheinCell Therapeutics GmbH
  • RhoVac AB
  • RS Research
  • Rubicon Biotechnology Inc
  • Sanofi
  • Sathgen Biotech
  • Selexel Sarl
  • Semorex Inc
  • Senhwa Biosciences Inc
  • Sensei Biotherapeutics Inc
  • Serometrix LLC
  • Shenogen Pharma Group Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sierra Oncology Inc
  • Silenseed Ltd
  • Sophiris Bio Inc
  • Soricimed Biopharma Inc
  • Sorrento Therapeutics Inc
  • Sotio AS
  • SynDevRx Inc
  • TaiGen Biotechnology Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Takis Srl
  • Targovax ASA
  • Terpenoid Therapeutics Inc
  • Tesaro Inc
  • Teva Pharmaceutical Industries Ltd
  • Theravectys SA
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • TREAT U SA
  • Trovagene Inc
  • Tyg Oncology Ltd
  • Tyme Technologies Inc
  • UbiVac LLC
  • Ultimovacs AS
  • Vaccibody AS
  • Vaccitech Ltd
  • ValiRx Plc
  • Vasgen Ltd
  • Vault Pharma Inc
  • Vaxeal Holding SA
  • Vaxon Biotech
  • Vicore Pharma AB
  • Vicus Therapeutics LLC
  • Viralytics Ltd
  • ViraTherapeutics GmbH
  • VLP Therapeutics LLC
  • WntResearch AB
  • Xencor Inc
  • Zenith Epigenetics Ltd
  • Zhejiang Conba Pharmaceutical Co Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll